Effects of antivirals on patients with COVID-19 breakthrough.

ABSTRACT:

Background

Antivirals have been given widely for patients with COVID-19 breakthrough in Asian countries, creating a "black market" for unapproved and unprescribed medications. More evidence is needed to clarify the benefits of antivirals in these settings.

Methods

We conducted a random-sampling retrospective cohort study at a general hospital in Vietnam. We recruited patients with mild-to-moderate COVID-19 breakthrough who were given either standard of care (SoC) alone or SoC + antiviral. Primary outcome was residual respiratory symptoms that lasted > 7 days. Secondary outcome was long COVID-19, diagnosed by specialized physicians. We used logistic regression to measure odds ratio (OR), in addition to a sensitivity and subgroup analyses to further explore the results.

Res

SUBMITTER: Pham HT 

PROVIDER: S-EPMC10763260 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature